

Channing J Paller

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8932460/channing-j-paller-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

65
papers

3,830
citations

21
h-index

61
g-index

69
ext. papers

4,924
ext. citations

6
avg, IF

5.12
L-index

#	Paper	IF	Citations
65	AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. <i>New England Journal of Medicine</i> , 2014 , 371, 1028-38	59.2	1753
64	Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2015 , 1, 582-91	13.4	441
63	Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2020 , 6, 650-659	13.4	297
62	Sex-based differences in pain perception and treatment. <i>Pain Medicine</i> , 2009 , 10, 289-99	2.8	233
61	Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. <i>Clinical Advances in Hematology and Oncology</i> , 2013 , 11, 14-23	0.6	107
60	Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study. <i>Lancet Oncology</i> , 2018 , 19, 76-86	21.7	100
59	A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination. <i>Prostate</i> , 2015 , 75, 1518-25	4.2	70
58	A phase II randomized trial of Observation versus stereotactic ablative Radiation for Oligometastatic prostate CancEr (ORIOLE). <i>BMC Cancer</i> , 2017 , 17, 453	4.8	60
57	Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials. <i>Antioxidants</i> , 2018 , 7,	7.1	46
56	Relationship of sex steroid hormones with bone mineral density (BMD) in a nationally representative sample of men. <i>Clinical Endocrinology</i> , 2009 , 70, 26-34	3.4	46
55	Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study. <i>Prostate</i> , 2016 , 76, 1218-26	4.2	45
54	Design of phase I combination trials: recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee. <i>Clinical Cancer Research</i> , 2014 , 20, 4210-7	12.9	41
53	PSMA Theranostics: Review of the Current Status of PSMA-Targeted Imaging and Radioligand Therapy. <i>Cancers</i> , 2020 , 12,	6.6	35
52	Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. <i>Journal of the National Cancer Institute</i> , 2019 , 111, 118-128	9.7	33
51	TGF- β receptor I inhibitor enhances response to enzalutamide in a pre-clinical model of advanced prostate cancer. <i>Prostate</i> , 2019 , 79, 31-43	4.2	29
50	Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial. <i>Clinical Cancer Research</i> , 2018 , 24, 306-315	12.9	24
49	Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 275-282.e1	3.3	22

48	Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer. <i>Cancer Medicine</i> , 2014 , 3, 1322-35	4.8	22
47	TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1371-1382	2.2	22
46	Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 105, 948-956	4	21
45	Sarcomatoid Carcinoma of the Prostate: Retrospective Review of a Case Series From the Johns Hopkins Hospital. <i>Urology</i> , 2015 , 86, 539-43	1.6	21
44	Management of bone metastases in refractory prostate cancer--role of denosumab. <i>Clinical Interventions in Aging</i> , 2012 , 7, 363-72	4	20
43	Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate Cancer. <i>European Urology Oncology</i> , 2021 , 4, 447-455	6.7	20
42	Detection fidelity of AR mutations in plasma derived cell-free DNA. <i>Oncotarget</i> , 2017 , 8, 15651-15662	3.3	19
41	Association between sex steroid hormones and hematocrit in a nationally representative sample of men. <i>Journal of Andrology</i> , 2012 , 33, 1332-41		18
40	Challenges of conducting clinical trials of natural products to combat cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2016 , 14, 447-55	0.6	18
39	A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts. <i>European Urology</i> , 2021 , 79, 692-699	10.2	17
38	Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. <i>Journal of Urology</i> , 2019 , 201, 735-741	2.5	16
37	Practical Considerations and Challenges for Germline Genetic Testing in Patients With Prostate Cancer: Recommendations From the Germline Genetics Working Group of the PCCTC. <i>JCO Oncology Practice</i> , 2020 , 16, 811-819	2.3	16
36	Genetic Alterations Detected in Cell-Free DNA Are Associated With Enzalutamide and Abiraterone Resistance in Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	15
35	Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies. <i>Prostate</i> , 2016 , 76, 512-20	4.2	15
34	Sipuleucel-T for the treatment of metastatic prostate cancer: promise and challenges. <i>Human Vaccines and Immunotherapeutics</i> , 2012 , 8, 509-19	4.4	15
33	Circulating Tumor DNA as a Marker of Therapeutic Response in Patients With Renal Cell Carcinoma: A Pilot Study. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, e515-e520	3.3	15
32	A pilot study of prostate-specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer. <i>Prostate</i> , 2019 , 79, 1597-1603	4.2	14
31	Comparison of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis. <i>JAMA Oncology</i> , 2021 , 7, 412-420	13.4	14

30	The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited. <i>European Urology</i> , 2021 , 80, 632-640	10.2	14
29	Racial Inequality in Prostate Cancer Outcomes-Socioeconomics, Not Biology. <i>JAMA Oncology</i> , 2019 , 5, 983-984	13.4	12
28	Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 387-395	4	11
27	Functionally Enigmatic Genes in Cancer: Using TCGA Data to Map the Limitations of Annotations. <i>Scientific Reports</i> , 2020 , 10, 4106	4.9	10
26	Evolving Intersection Between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper From the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. <i>JCO Precision Oncology</i> , 2018 , 2018,	3.6	10
25	PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 470-475.e3	3.3	9
24	Factors Affecting Combination Trial Success (FACTS): Investigator Survey Results on Early-Phase Combination Trials. <i>Frontiers in Medicine</i> , 2019 , 6, 122	4.9	7
23	State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research-NCI Strategic Workshop Highlights of Discussion Report. <i>Journal of the National Cancer Institute Monographs</i> , 2017 , 2017,	4.8	7
22	A phase II randomized trial of Radium-223 dichloride and SABR Versus SABR for oligometastatic prostate cancer (RAVENS). <i>BMC Cancer</i> , 2020 , 20, 492	4.8	6
21	Therapeutic Potential of PARP Inhibitors in the Treatment of Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2020 , 12,	6.6	6
20	The Society for Integrative Oncology Practice Recommendations for online consultation and treatment during the COVID-19 pandemic. <i>Supportive Care in Cancer</i> , 2021 , 29, 6155-6165	3.9	5
19	Muscadine grape skin extract inhibits prostate cancer cells by inducing cell-cycle arrest, and decreasing migration through heat shock protein 40. <i>Heliyon</i> , 2019 , 5, e01128	3.6	5
18	Long-Term Control of Oligometastatic Prostate Cancer After Stereotactic Body Radiotherapy in the Absence of Androgen Deprivation Therapy: A Case Report. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e839-e842	3.3	4
17	Comparison of Treatments for Nonmetastatic Castration-Resistant Prostate Cancer: Matching-Adjusted Indirect Comparison and Network Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	4
16	Lu-PSMA Radioligand Therapy Is Favorable as Third-Line Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. <i>Biomedicine</i> , 2021 , 9,	4.8	4
15	Bipolar androgen therapy sensitizes castration-resistant prostate cancer to subsequent androgen receptor ablative therapy. <i>European Journal of Cancer</i> , 2021 , 144, 302-309	7.5	3
14	A phase II randomized placebo-controlled double-blind study of salvage radiation therapy plus placebo versus SRT plus enzalutamide with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). <i>BMC Cancer</i> , 2019 , 19, 572	4.8	2
13	Risk factors for metastatic prostate cancer: A sentinel event case series. <i>Prostate</i> , 2017 , 77, 1366-1372	4.2	2

12	Relationship of sex steroid hormones with bone mineral density of the lumbar spine in adult men. <i>Bone and Joint Research</i> , 2020 , 9, 139-145	4.2	1
11	Finasteride and prostate cancer: a commentary. <i>Oncologist</i> , 2012 , 17, 888-90	5.7	1
10	Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics.. <i>Prostate Cancer and Prostatic Diseases</i> , 2022 ,	6.2	1
9	Val16A SOD2 Polymorphism Promotes Epithelial-Mesenchymal Transition Antagonized by Muscadine Grape Skin Extract in Prostate Cancer Cells. <i>Antioxidants</i> , 2021 , 10,	7.1	1
8	Efficacy of systemic therapies in men with metastatic castration resistant prostate cancer harboring germline ATM versus BRCA2 mutations. <i>Prostate</i> , 2021 , 81, 1382-1389	4.2	1
7	A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer. <i>Kidney Cancer</i> , 2022 , 1-13	0.6	1
6	Cost-Effectiveness of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer: An Economic Evaluation Based on Network Meta-Analysis.. <i>Value in Health</i> , 2022 , 25, 796-802	3.3	0
5	Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.. <i>European Urology Open Science</i> , 2021 , 34, 70-78	0.9	0
4	Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern. <i>World Journal of Nuclear Medicine</i> , 2019 , 18, 424-427	0.6	0
3	Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216).. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102517	2.2	0
2	Best Approaches and Updates for Prostate Cancer Biochemical Recurrence.. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022 , 42, 1-8	7.1	0
1	Considerations Regarding a Network Meta-analysis of Systemic Treatments for Metastatic Castration-Sensitive Prostate Cancer-Reply. <i>JAMA Oncology</i> , 2021 , 7, 1069-1070	13.4	